alexa Expression Of Integrin Receptors And Their Ligands In Papillary Thyroid Carcinoma With Different BRAF V600E Mutation Status
ISSN: 2153-0645

Journal of Pharmacogenomics & Pharmacoproteomics
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

2nd International Conference on Predictive, Preventive and Personalized Medicine & Molecular Diagnostics
November 03-05, 2014 Embassy Suites Las Vegas, USA

Galina P Logacheva, L A Mostovich, S V Svyatchenko, S P Shevchenko and L F Gulyaeva
Posters: J Pharmacogenomics Pharmacoproteomics
DOI: 10.4172/2153-0645.S1.003
Papillary thyroid cancer (PTC) is the most common malignancy of the endocrine system. The most frequent genetic alteration in PTC is V600E mutation in BRAF gene which leads to changes in the activity of intracellular signaling pathways. As a result, expression levels of cell membrane integrin receptors and their ligands - extracellular matrix proteins - osteopontin (OPN) and thrombospondin-1 (TSP1) change. Such changes promote migration, invasion and metastasis of tumor cells. Thus, integrin receptors and their ligands are potential biomarkers of an aggressive PTC phenotype. The aim of our study was to compare the gene expression profile of integrins ITGA3, ITGAV, ITGA6, ITGA9, ITGB1 and their ligands OPNa, OPNb, and TSP1 in PTC with different BRAF V600E mutation status.Intraoperative thyroid tissue samples from 41 patients diagnosed with papillary thyroid carcinoma (n=26), diffuse nodular nontoxic goiter (n=10) and follicular adenoma (n=5) were analyzed to evaluate the expression levels of the investigated genes that had been determinedby real time RT-PCR. Immunohistochemistrywas usedto confirm the PCR results and to estimate the amount of protein products.The presence ofBRAF V600E mutation was identified using allele-specific amplification. In this study asignificant increase (p>0.05) in expression levelsof ITGA3, ITGAV, ITGB1, OPNb and TSP1was observed in the PTC tissue samples.The expression levels of ITGA3 and ITGAV were higher in the BRAF V600Epositive PTC samples. The observed changes in the expression levels of the studied genes indicate their potential role in tumor progression and the possible impact on their expression of the mutant product of gene BRAF.Integrins and their ligands OPN and TSP1 can be considered to be potential markers in determining the prognosis and treatment of PTC.
Galina P Logacheva graduated from Medical department of Novosibirsk State University (NSU) in July 2014. Since September 2014, she has been a clinical intern in Oncology on the base of NSU and a junior doctor of the head and neck tumor department in Novosibirsk Clinical Hospital 1. She is also engaged in research work and has participated in student and oncological conferences.
image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version